The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson’s disease, the bilaterally MPTP-treated rhesus monkey
The propargylamine CGP 3466B prevents dopamine cell death both in vitro and in rodent models of Parkinson’s disease. The present study investigates the efficacy of this compound to prevent the behavioral consequences of dopaminergic cell death in the best animal model of Parkinson’s disease, the bilaterally MPTP-treated monkey. Rhesus monkeys were bilaterally treated with MPTP, using a two-step procedure: 2.50 mg MPTP was infused into the left carotid artery followed by a second bolus of 1.25 mg into the right carotid artery, 8 weeks later. Subcutaneous injection of either 0.014 mg/kg CGP 3466B (n = 4) or its solvent (distilled water; n = 4), twice daily for fourteen days, started two hours after the second MPTP infusion. A Parkinson rating scale was assessed for the evaluation of the effects. After the first MPTP treatment, the monkeys developed mild to moderate parkinsonian symptoms. The second MPTP treatment strongly increased the severity of Parkinson scores in all control monkeys, as assessed on day 3, 7, 14, 21, 28 and 35 after the second MPTP treatment. In contrast, CGP 3466B nearly completely prevented the increase of parkinsonian symptoms after the second MPTP treatment. The therapeutic effects of CGP 3466B were still present after a washout period of 3 weeks, implying that the effects were not symptomatic. These data are the first to show that the systemic administration of CGP 3466B is able to prevent the development of MPTP-induced motor symptoms in primates. This compound may have great value for inhibiting the progression of the neurodegenerative process in patients with Parkinson’s disease.
KeywordsParkinsonian Syndrome Parkinsonian Symptom MPTP Treatment Impaired Gait MPTP Injection
Unable to display preview. Download preview PDF.
- Andringa G (2000) Evaluation of new treatment strategies of Parkinson’s disease in animal models: the therapeutic efficacy of the dopamine D1 antagonist SKF 83959 and the neuroprotective agent CGP 3466B. Print Partners Ipskamp, Enschede, Netherlands, 99–115Google Scholar
- Andringa G, Vermeulen RJ, Drukarch B, Renier WO, Stoof JC, Cools AR (1999a) The validity of the pre-treated, unilaterally MPTP-treated monkey as model of Parkinson’s disease: a detailed behavioral analysis of the therapeutic and undesired effects of the D2 agonist LY 171555 and the D1 agonist SKF 81927. Beh Pharmacol 10(2): 163–173CrossRefGoogle Scholar
- Andringa G, Lubbers L, Drukarch B, Stoof JC, Cools AR (1999b) The predictive validity of the drug-naive bilaterally MPTP-treated monkey as model of Parkinson’s disease: effects of L-DOPA and the D1 agonist SKF 82958. Beh Pharmacol 10(2): 175182Google Scholar
- Guttman M, Fibiger HC, Jakubovic A, Calne DB (1990) Intracarotid 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine administration: Biochemical and behavioural observations in a primate model of hemiparkinsonism. J Neurochem 54: 13291334Google Scholar
- Kato AC, Bernheim L, Waldmeier P, Sagot Y, (1997) CGP 3466B, a dibenzoxepine derivate, increases life-span in an animal model of motoneuron disease. Soc Neurosci Abstr 23(554) (abstr no 215.14)Google Scholar
- Paterson IA, Fennig CJ, Gelowitz DL, Waldmeier P, Boulton AA (1998a) CGP3466 prevents neuronal death in models of ischaemia and seizure in vivo. J Neurochem 70 Suppl 1: S6C (Abstract)Google Scholar
- Paterson IA, Waldmeier P, Boulton AA (1998b) CGP 3466 and CGP 3466B prevent cytosine arabinoside-induced apoptosis in cultures of cerebellar neurones. J Neurochem 70 Suppl 1: S11B (Abstract)Google Scholar
- Sunaga K, Takahashi H, Chuang DM, Ishitani R (1995) Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer’s brain. Neurosci Lett 200: 133–136PubMedCrossRefGoogle Scholar
- Waldmeier P, Boulton AA, Cools AR, Kato AC, Tatton WG (2000) Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm Suppl 6Google Scholar
- Authors’ address: A. R. Cools, Department of Psychoneuropharmacology, P.O. Box. 9101, Faculty of Medicine, University of Nijmegen, 6500 HB, Nijmegen, The Netherlands. Email: A.Cools@pnf.kun.nl Google Scholar